Na-dependent dopamine transporter
| Catalog# | Product Description | Host Species | Nature | Cross reactivity | Quantity | Volume | Price |
|---|---|---|---|---|---|---|---|
| DAT-101AP | Na-dependent dopmaine transporter antibodies | Rabbit | AP | r, m, h, others | 100.0 ug | 150-500 ul |
$245.00
|
| FITC-DAT1 | FITC-conjugated DAT antibodies | Rabbit | FITC-AP | r, m, h, others | 100.0 ug | 150-500 ul |
$350.00
|
| P-DAT1 | Antigenic blocking peptide for DAT | n/a | Synthetic peptide | n/a | 250.0 ug | 100 ul |
$125.00
|
| PC-DAT1 | WB positive control for DAT | n/a | Protein in ready-to-use buffer | n/a | 0.0 ug | 150 ul |
$185.00
|
Solute carrier family 6, member 3 which is commonly known as sodium-dependent dopamine transporter (DAT1) is a plasma membrane transport protein located on human chromosome 15p15.3 (1). It belongs to the sodium and chloride-dependent neurotransmitter transporter family and plays a key role in controlling dopamine-mediated neurotransmission (2). The 3’ untranslated region of this gene contains a 40bp variable number of tandem repeats, which can be present in 3-11 copies. Variations in the number of repeats of this VNTR have been implicated in various disorders including attention deficit hyperactivity disorder (ADHD), alcohol and nicotine addiction, parkinson’s disease (PD) and idiopathic epilepsy (3). The allele with 10 copies of this sequence has been implicated in dopamine transporter density in mammals (4). Studies have found abnormal densities of dopamine transporter in the brain region of patients with ADHD. Stimulant medications such as amphetamine and methylphenidate which are efficient in reducing ADHD symptoms inhibit the dopamine transporter and dopamine uptake and treatment with these medications decreases the densities of DAT1 in the brain region. Therefore, DAT1 is a promising target in treatment of ADHD (5).
The 3’ untranslated region of DAT1 is also associated with cold pain tolerance. This gene was shown to interact with early drug exposure (heavy or regular) of the maturing adolescent brain to predict substance use or abuse in young adulthood; therefore, it is also associated with alcohol and nicotine consumption (6). Recently it was reported that the promoter region of DAT1 is implicated in the etiology of schizophrenia and the immunoreactivity of this gene is significantly reduced in peripheral blood lymphocytes in parkinson’s disease (7). DAT1 is expressed in the brain and it is approximately a 74.4kDa protein (620 amino acids).
The SLC6A3 antibodies were generated using peptide corresponding to human SLC6A3 protein. SLC6A3 antibodies are affinity purified over immobilized antigen based affinity chromatography, and the purified immunoglobulins are stabilized in antibody stabilization buffer. FabGennix Int. Inc. will provide limited quantities of antigenic blocking protein for competition assays involving SLC6A3 antibodies. Antibodies to SLC6A3 (DAT-101AP) will label ~74.4kDa protein in Western blot positive control for SLC6A3 (PC-DAT1) and several other tissues. FabGennix Inc. will conjugate this and other antibodies from its catalog to either secondary enzymes (alk-Pase or HRP) or fluorescent probes at a nominal cost upon request. FabGennix also provides custom antibody production services for researchers that are looking for high affinity mono and polyclonal antibodies in various species. We specialize in making application specific antibodies that are useful in IHC, confocal and other applications where native antigen is detected.
For research use only, not for diagnostic or therapeutic use.
Data Sheets
MSDS
General Information
Citations
Search FabGennix Product Citation Data Base
Search